The gene adenosine deaminase, RNA specific (ADAR)/ ADAR1, spanning ~30Kbp on genomic DNA, is mapped to human chromosome 1q21.3. The encoded protein exists in two isoforms, namely ADAR1L and ADAR1S with molecular weight of 150kDa and 110kDa, respectively. ADAR protein contains conserved catalytic deaminase domain (DM) at C-terminal and two or three dsRNA-binding domains (dsRBDs) at the N-terminal end. The protein is expressed in wide variety of tissues, including the central nervous system (CNS).
Synonyms: Anti-136 kDa double-stranded RNA-binding protein antibody produced in rabbit; Anti-DRADA antibody produced in rabbit; Anti-Double-stranded RNA-specific adenosine deaminase antibody produced in rabbit; Anti-IFI-4 protein antibody produced in rabbit; Anti-Interferon-inducible protein 4 antibody produced in rabbit; Anti-K88DSRBP antibody produced in rabbit; Anti-P136 antibody produced in rabbit
Storage: -20C
Application: Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.Immunofluorescence (1 paper)Western Blotting (1 paper)
Biochem Physiol Actions: Adenosine deaminase, RNA specific (ADAR)/ ADAR1 catalyzes the hydrolytic deamination of adenosine (A) to inosine (I) in double-stranded (ds) RNAs. It plays a vital role in RNA editing. Mutation in the gene is associated with the development of Dyschromatosis symmetrica hereditaria (DSH) and autoimmune disorder Aicardi-Goutières syndrome (AGS). In addition, it is also a candidate gene for seizure disorders. Elevated expression of ADAR1 has been observed in breast cancer patients.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC